research reports and media, page-2307

I agree with Denial/Dungiven that the market expects a cap raise and there is a decent chance it happens.

However (this could be wishful thinking) they have approx $60m on hand, they are due a tax rebate of circa $10m very soon. This will take them some time into the future, their burn rate isnt that high. Could they benefit from waiting for a release of more data / announcements like MPS/chronic heart failure (both of which PR was very +ve on the investor conf). Can they get some funding from those to programmes over the next few months? Who knows

Re OA - Let’s assume 008 is september 22 (which I think sounds very conservative), that is certainly cutting it a bit fine but the cash is currently there to take them into late 22/23 and if they can show big pharma some early readouts on 008 in q1 22 (which they can under NDA whereby it doesnt get shown to the market) i would imagine they can sign a small regional deal to get them over the hump.

Like many have said here, i also dont think a cap raise needs to be overly large or dilutive or deeply discounted and if they do that it should at least clear up one of the major concerns in the market.

DYOR